EXCLUSIVE: Imunon Says Phase 2 IMNN-001 Data Showed Lower MRD, Higher ctDNA Clearance And Favorable Safety In Frontline Ovarian Cancer; Preliminary Data Reinforces Immunotherapy’s Potential For Success In Currently Recruiting Phase 3 OVATION 3 Study